ID   K562/etop20
AC   CVCL_Y168
DR   CGH-DB; 9122-4
DR   Wikidata; Q54899410
RX   PubMed=14973057;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 29-06-23; Version: 15
//
RX   PubMed=14973057; DOI=10.1158/0008-5472.CAN-3263-2;
RA   Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A.,
RA   Funato T., Yokomizo A., Naito S., Imoto I., Tsuruo T., Inazawa J.;
RT   "Alteration in copy numbers of genes as a mechanism for acquired drug
RT   resistance.";
RL   Cancer Res. 64:1403-1410(2004).
//